Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P04141 (
granulocyte-macrophage colony-stimulating factor
)
6,790
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Dendritic cells (DC) are professional antigen-presenting cells (APC) within the immune system and antigen-pulsed DC can be used as an effective vaccine for active immunotherapy of cancer.
Granulocyte-macrophage colony-stimulating factor
(
GM-CSF
) plays an important role in the generation of DC. We previously showed that
GM-CSF
can induce murine erythroleukaemia cells (
FBL
-3) to differentiate into monocyte-like cells. To develop a new vaccinating method to stimulate the host immune response to leukaemia, we further investigate whether
FBL
-3 cells induced by
GM-CSF
can differentiate into DC in the present study. After being treated with
GM-CSF
,
FBL
-3 cells expressed high levels of 33D1 and NLDC-145, which are the specific markers of DC. The expression of MHC-II, B7-1, B7-2 and vascular cell adhesion molecule-1 (VCAM-1) was up-regulated markedly; the typical morphology of DC were also observed by electron microscopy. Functionally, the
GM-CSF
-induced
FBL
-3 cells could apparently stimulate the proliferation of naive allogeneic and autologous T lymphocytes and induce the generation of specific CTL more efficiently than the wild-type
FBL
-3 cells. Mice immunized with
GM-CSF
-induced
FBL
-3 cells could resist the subsequent challenge with the wild-type
FBL
-3 cells. Collectively, these data indicate that
GM-CSF
differentiates murine erythroleukaemia cells into DC phenotypically, morphologically and functionally.
FBL
-3-derived DC can be used as a new type of vaccine. Our results may have important implications for the immunotherapy of leukaemia.
...
PMID:Granulocyte-macrophage colony-stimulating factor induces the differentiation of murine erythroleukaemia cells into dendritic cells. 976 69